Anecortave
From Wikipedia, the free encyclopedia
 |
|
|
Anecortave
|
|
| Systematic (IUPAC) name | |
| [2-[(8R,10S,13S,14R,17R)- 17-hydroxy-10,13-dimethyl-3-oxo- 2,6,7,8,12,14,15,16-octahydro- 1H-cyclopenta[a]phenanthren-17-yl]- 2-oxo-ethyl] acetate |
|
| Identifiers | |
| CAS number | 7753-60-8 |
| ATC code | S01XA16 |
| PubChem | 111332 |
| DrugBank | ? |
| Chemical data | |
| Formula | C23H30O5 |
| Mol. weight | 386.48 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Schedule 4 (Aust) |
| Routes | intravitreal depot injection |
Anecortave (rINN) (IPA: [ænəˈkɔteɪv]) is a novel angiogenesis inhibitor used in the treatment of the exudative (wet) form of age-related macular degeneration. Although based on a steroid nucleus, it possesses little glucocorticoid activity. It is marketed by Alcon as anecortave acetate for depot suspension under the trade name Retaane.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
